File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Entecavir versus lamivudine prophylaxis without hepatitis B immune globulin after liver transplantation for chronic hepatitis B

TitleEntecavir versus lamivudine prophylaxis without hepatitis B immune globulin after liver transplantation for chronic hepatitis B
Authors
Fung, JChan, SCCheung, CKYChok, KSHSharr, WChan, ACDai, WCCheung, TTFan, STLai, CLYuen, MFLo, CM
KeywordsMedical sciences
Gastroenterology medical sciences
Surgery
Issue Date2012
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
Citation
The 18th Annual International Congress of the International Liver Transplantation Society (ILTS 2012), San Francisco, CA., 12-15 May 2012. In Liver Transplantation, 2012, v. 18 suppl. S1, p. S124, abstract O-126 How to Cite?
DOI: http://dx.doi.org/10.1002/lt.23435
AbstractBACKGROUND: Oral antiviral prophylaxis without hepatitis B immune globulin (HBIG) has been shown to be effective after liver transplantation for hepatitis B, although the efficacy of different nucleoside/nucleotide analogues is not known. The current study compares the efficacy of entecavir (ETV) versus lamivudine (LAM). PATIENTS AND METHODS: From January 2003 to March 2011, 292 consecutive patients either taking LAM (n=163) or ETV (n=129) as mono-prophylaxis after liver transplantation were included. None of the patients received HBIG …
DescriptionOral Presentation - Concurrent Session: Recurrent Disease/Pathology: abstract no. O-126
Young Investigator Award Winners: James Fung
This journal suppl. entitled: Supplement: The ILTS 18th Annual International Congress
Persistent Identifierhttp://hdl.handle.net/10722/186822
ISSN
1527-6465
2021 Impact Factor: 6.112
2020 SCImago Journal Rankings: 1.814

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_US
dc.contributor.authorChan, SCen_US
dc.contributor.authorCheung, CKYen_US
dc.contributor.authorChok, KSHen_US
dc.contributor.authorSharr, Wen_US
dc.contributor.authorChan, ACen_US
dc.contributor.authorDai, WCen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, MFen_US
dc.contributor.authorLo, CMen_US
dc.date.accessioned2013-08-20T12:21:09Z-
dc.date.available2013-08-20T12:21:09Z-
dc.date.issued2012en_US
dc.identifier.citationThe 18th Annual International Congress of the International Liver Transplantation Society (ILTS 2012), San Francisco, CA., 12-15 May 2012. In Liver Transplantation, 2012, v. 18 suppl. S1, p. S124, abstract O-126en_US
dc.identifier.issn1527-6465-
dc.identifier.urihttp://hdl.handle.net/10722/186822-
dc.descriptionOral Presentation - Concurrent Session: Recurrent Disease/Pathology: abstract no. O-126-
dc.descriptionYoung Investigator Award Winners: James Fung-
dc.descriptionThis journal suppl. entitled: Supplement: The ILTS 18th Annual International Congress-
dc.description.abstractBACKGROUND: Oral antiviral prophylaxis without hepatitis B immune globulin (HBIG) has been shown to be effective after liver transplantation for hepatitis B, although the efficacy of different nucleoside/nucleotide analogues is not known. The current study compares the efficacy of entecavir (ETV) versus lamivudine (LAM). PATIENTS AND METHODS: From January 2003 to March 2011, 292 consecutive patients either taking LAM (n=163) or ETV (n=129) as mono-prophylaxis after liver transplantation were included. None of the patients received HBIG …-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021-
dc.relation.ispartofLiver Transplantationen_US
dc.rightsLiver Transplantation. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectGastroenterology medical sciences-
dc.subjectSurgery-
dc.titleEntecavir versus lamivudine prophylaxis without hepatitis B immune globulin after liver transplantation for chronic hepatitis Ben_US
dc.typeConference_Paperen_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_US
dc.identifier.emailCheung, CKY: cindycky@hku.hken_US
dc.identifier.emailSharr, W: wwsharr@hku.hken_US
dc.identifier.emailChan, AC: acchan@hku.hken_US
dc.identifier.emailDai, WC: daiwc@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, MF: mfyuen@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityChan, AC=rp00310en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/lt.23435-
dc.identifier.hkuros210988en_US
dc.identifier.hkuros218436-
dc.identifier.volume18en_US
dc.identifier.issuesuppl. S1en_US
dc.identifier.spageS124, abstract O-126en_US
dc.identifier.epageS124, abstract O-126en_US
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 140704-
dc.identifier.issnl1527-6465-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats